Because of advances in linker conjugation chemistry and our understanding of the ADC mechanism of action in vivo, an increasing breadth of anticancer agents are now being incorporated in newer ADC ...
BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented preclinical data ...
Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback